CN101827851A - 用于治疗肿瘤的5-氰基噻吩并吡啶 - Google Patents

用于治疗肿瘤的5-氰基噻吩并吡啶 Download PDF

Info

Publication number
CN101827851A
CN101827851A CN200880112035A CN200880112035A CN101827851A CN 101827851 A CN101827851 A CN 101827851A CN 200880112035 A CN200880112035 A CN 200880112035A CN 200880112035 A CN200880112035 A CN 200880112035A CN 101827851 A CN101827851 A CN 101827851A
Authority
CN
China
Prior art keywords
amino
pyridine
carboxamide
thieno
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880112035A
Other languages
English (en)
Chinese (zh)
Inventor
G·赫尔策曼
U·格拉德勒
H·格雷纳尔
C·阿门特
D·穆斯尔
P·希勒茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN101827851A publication Critical patent/CN101827851A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880112035A 2007-10-16 2008-09-19 用于治疗肿瘤的5-氰基噻吩并吡啶 Pending CN101827851A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007049451A DE102007049451A1 (de) 2007-10-16 2007-10-16 5-Cyano-thienopyridine
DE102007049451.5 2007-10-16
PCT/EP2008/007888 WO2009049743A1 (de) 2007-10-16 2008-09-19 5-cyano-thienopyridine zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
CN101827851A true CN101827851A (zh) 2010-09-08

Family

ID=40262956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880112035A Pending CN101827851A (zh) 2007-10-16 2008-09-19 用于治疗肿瘤的5-氰基噻吩并吡啶

Country Status (16)

Country Link
US (1) US8202882B2 (de)
EP (1) EP2197886B1 (de)
JP (1) JP5480811B2 (de)
KR (1) KR20100076026A (de)
CN (1) CN101827851A (de)
AR (1) AR068872A1 (de)
AU (1) AU2008314245B2 (de)
BR (1) BRPI0818170A2 (de)
CA (1) CA2702551A1 (de)
DE (1) DE102007049451A1 (de)
EA (1) EA201000618A1 (de)
ES (1) ES2401936T3 (de)
IL (1) IL205137A0 (de)
MX (1) MX2010004017A (de)
WO (1) WO2009049743A1 (de)
ZA (1) ZA201003425B (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103936757A (zh) * 2013-01-18 2014-07-23 上海昀怡健康管理咨询有限公司 五元并六元杂环化合物、其制备方法、药物组合物和应用
CN104220426A (zh) * 2012-03-20 2014-12-17 塞拉根制药公司 雌激素受体调节剂及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7904970B2 (en) 2009-02-20 2011-03-15 J-Brem, LLC Headwear with features for holding eyeglasses
CA2789021C (en) 2010-02-05 2018-02-06 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
ES2528441T3 (es) 2010-02-22 2015-02-10 Merck Patent Gmbh Hetarilaminonaftiridinas
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
WO2015065716A1 (en) * 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
AU2016229918B2 (en) 2015-03-08 2020-10-29 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
EP3548035A4 (de) 2016-11-30 2020-07-22 Case Western Reserve University Kombinationen von 15-pgdh-inhibitoren mit corticosteroiden und/oder tnf-inhibitoren und verwendungen davon
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
WO2005058315A1 (en) 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
DE102005009440A1 (de) * 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
DE102005024245A1 (de) 2005-05-27 2006-11-30 Merck Patent Gmbh Thienopyridine

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104220426A (zh) * 2012-03-20 2014-12-17 塞拉根制药公司 雌激素受体调节剂及其用途
CN104220426B (zh) * 2012-03-20 2017-03-01 塞拉根制药公司 雌激素受体调节剂及其用途
CN103936757A (zh) * 2013-01-18 2014-07-23 上海昀怡健康管理咨询有限公司 五元并六元杂环化合物、其制备方法、药物组合物和应用
CN103936757B (zh) * 2013-01-18 2019-09-13 广州再极医药科技有限公司 五元并六元杂环化合物、其制备方法、药物组合物和应用

Also Published As

Publication number Publication date
WO2009049743A1 (de) 2009-04-23
BRPI0818170A2 (pt) 2017-05-16
ES2401936T3 (es) 2013-04-25
JP5480811B2 (ja) 2014-04-23
AU2008314245B2 (en) 2013-07-18
EP2197886B1 (de) 2012-12-26
AU2008314245A1 (en) 2009-04-23
MX2010004017A (es) 2010-04-27
AR068872A1 (es) 2009-12-09
US20100234369A1 (en) 2010-09-16
IL205137A0 (en) 2010-11-30
EA201000618A1 (ru) 2011-04-29
JP2011500610A (ja) 2011-01-06
EP2197886A1 (de) 2010-06-23
DE102007049451A1 (de) 2009-04-23
KR20100076026A (ko) 2010-07-05
CA2702551A1 (en) 2009-04-23
US8202882B2 (en) 2012-06-19
ZA201003425B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
CN101827851A (zh) 用于治疗肿瘤的5-氰基噻吩并吡啶
CN101346383B (zh) 三唑衍生物
EP2291375B1 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
ES2470681T3 (es) Derivados de Imidazotiadiazol
CN102015724A (zh) 噻吩并嘧啶类
CN102596200A (zh) 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类
CN102227426A (zh) 作为自分泌运动因子抑制剂的苯并萘啶化合物
CN101679425A (zh) 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途
CN103946223B (zh) 3‑氰基芳基‑1H‑吡咯并[2,3‑b]吡啶衍生物
CN103596938A (zh) 噻唑衍生物
CN103403005B (zh) 5-([1,2,3]-三唑-4-基)-7H-吡咯并[2,3-d]嘧啶衍生物
CN102666544B (zh) 吡咯并[2,3-d]吡嗪-7-基嘧啶化合物
CN104736543A (zh) 用于治疗肿瘤的7-氮杂吲哚-2,7-二氮杂萘衍生物
CN102292339B (zh) 作为MetAP-2抑制剂的新杂环化合物
CN105307656B (zh) 巨噬细胞刺激1受体mst1r的喹啉抑制剂
JP2012530731A (ja) ＴＧＦ−β受容体キナーゼモジュレーターとしてのアルコキシ−チエノピリミジン
CN103764651A (zh) 适合治疗癌症疾病的7-氮杂吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147993

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100908

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1147993

Country of ref document: HK